Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Lung Cancer (Amsterdam, Netherlands)|May 8, 2023
Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trialTsuneo Shimokawa, Hiroaki Okamoto, Ryunosuke Machida, et al.
International Journal of Clinical Oncology|February 19, 2022
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LAThomas John, Hiroshi Sakai, Satoshi Ikeda, et al.
BMC Cancer|March 4, 2018
Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016Satoshi Ikeda, Terufumi Kato, Takashi Ogura, et al.
BMC Cancer|May 28, 2017
Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604Yuki Misumi, Hiroaki Okamoto, Jiichiro Sasaki, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2024
Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study)Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, et al.
Anticancer Research|December 3, 2024
Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?Yuri Taniguchi, Takao Shigenobu, Akiko Hayashi, et al.
JTO Clinical and Research Reports|December 4, 2023
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA StudyYasunori Murata, Shigeru Tanzawa, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology|February 17, 2025
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA studyShigeru Tanzawa, Hiroshige Yoshioka, Toshihiro Misumi, et al.
Therapeutic Advances in Medical Oncology|March 17, 2025
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA studyFumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi, et al.
Pageof 3